Mink Therapeutics Company Insiders
INKT Stock | USD 0.69 0.01 1.43% |
Slightly above 90 percent of all Mink Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Mink Therapeutics suggests that a fairly large number of insiders are very bullish. Mink Therapeutics employs about 31 people. The company is managed by 9 executives with a total tenure of roughly 73 years, averaging almost 8.0 years of service per executive, having 3.44 employees per reported executive.
Mink Therapeutics' Insider Buying Vs Selling
90
Selling | Buying |
Latest Trades
2023-10-16 | Agenus Inc | Acquired 429 @ 1.1 | View | ||
2023-10-12 | Agenus Inc | Acquired 3173 @ 1.1 | View | ||
2023-10-04 | Agenus Inc | Acquired 15001 @ 1.09 | View | ||
2023-08-28 | Agenus Inc | Acquired 12808 @ 1.45 | View | ||
2023-08-24 | Agenus Inc | Acquired 170244 @ 1.54 | View | ||
2023-05-10 | Agenus Inc | Acquired 22065 @ 1.51 | View | ||
2023-05-05 | Garo H Armen | Disposed 100000 @ 0.95 | View | ||
2023-05-03 | Agenus Inc | Acquired 128689 @ 1.08 | View | ||
2023-05-02 | Garo H Armen | Acquired 100000 @ 0.95 | View | ||
2022-07-18 | Ulf Wiinberg | Acquired 3339 @ 1.33 | View |
Monitoring Mink Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Mink |
Mink Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.9725) % which means that it has lost $0.9725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.3898) %, meaning that it created substantial loss on money invested by shareholders. Mink Therapeutics' management efficiency ratios could be used to measure how well Mink Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 3.51 in 2024, whereas Return On Tangible Assets are likely to drop (5.18) in 2024. At this time, Mink Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 15.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 4.3 M in 2024.Common Stock Shares Outstanding is likely to gain to about 36.9 M in 2024, whereas Net Loss is likely to drop (26.5 M) in 2024.
Mink Therapeutics Workforce Comparison
Mink Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,304. Mink Therapeutics claims roughly 31.0 in number of employees contributing just under 2% to equities under Health Care industry.
Mink Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mink Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mink Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mink Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Van Dijk Marcus Antonius over three months ago Acquisition by Van Dijk Marcus Antonius of 15000 shares of Mink Therapeutics subject to Rule 16b-3 | ||
Corvese Brian over three months ago Acquisition by Corvese Brian of 17967 shares of Mink Therapeutics at 0.99 subject to Rule 16b-3 | ||
Ryan Barbara over six months ago Acquisition by Ryan Barbara of 12158 shares of Mink Therapeutics at 1.46 subject to Rule 16b-3 | ||
Corvese Brian over six months ago Acquisition by Corvese Brian of 18816 shares of Mink Therapeutics at 0.95 subject to Rule 16b-3 | ||
Jennifer Buell over six months ago Acquisition by Jennifer Buell of 500000 shares of Mink Therapeutics subject to Rule 16b-3 | ||
Behner Peter over six months ago Acquisition by Behner Peter of 14784 shares of Mink Therapeutics subject to Rule 16b-3 | ||
Agenus Inc over a year ago Purchase by Agenus Inc of 3173 shares of Mink Therapeutics | ||
Jennifer Buell over a year ago Acquisition or disposition of Mink Therapeutics securities by Jennifer Buell |
Mink Therapeutics Notable Stakeholders
A Mink Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mink Therapeutics often face trade-offs trying to please all of them. Mink Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mink Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jennifer Buell | CEO President | Profile | |
Garo Armen | Executive Chairman | Profile | |
Robert Foster | Director Affairs | Profile | |
Kimberly Ha | Head Relations | Profile | |
Joy Zhou | Vice CMC | Profile | |
Marcus Dijk | Chief Officer | Profile | |
Heather Boussios | General Officer | Profile | |
Christine Klaskin | Treasurer | Profile | |
Patrick MBA | VP Operations | Profile |
About Mink Therapeutics Management Performance
The success or failure of an entity such as Mink Therapeutics often depends on how effective the management is. Mink Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mink management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mink management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (4.93) | (5.18) | |
Return On Capital Employed | 3.35 | 3.51 | |
Return On Assets | (4.93) | (5.18) | |
Return On Equity | 1.24 | 1.18 |
Please note, the imprecision that can be found in Mink Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mink Therapeutics. Check Mink Therapeutics' Beneish M Score to see the likelihood of Mink Therapeutics' management manipulating its earnings.
Mink Therapeutics Workforce Analysis
Traditionally, organizations such as Mink Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mink Therapeutics within its industry.Mink Therapeutics Manpower Efficiency
Return on Mink Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 724.4K | |
Net Loss Per Executive | 2.5M |
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.